Safeguard found for potential cancer therapy

November 16, 2000

Researchers who had been advancing a promising cancer treatment found a new obstacle looming last spring, when the international journal Nature Medicine published a study that identified a fatal flaw: The treatment destroys healthy human liver cells.

Now researchers at the University of Pennsylvania School of Medicine have discovered a solution to that crucial problem, re-opening what the lead scientist in Penn's efforts calls "a window of opportunity" for using this powerful treatment against colon, breast, lung, ovarian and esophageal cancers.

"There are only a handful of very promising anti-cancer drugs and this one is on that list," said Dr. Wafik El-Deiry, MD-PhD, associate professor of medicine at Penn. "Part of the reason we've been so excited about this treatment is because it seems to be very effective on a wide range of human cancers. It was on its way toward clinical trials, and then there was this set-back.

"But now we've solved the toxicity problem. Within the context of clinical trials, we should be able to protect the liver while still killing cancer cells," said El-Deiry, who also serves as assistant investigator for the Howard Hughes Medical Institute. Findings from his recent work are published in the current issue of Cancer Research, which is scheduled for publication Monday.

The therapy consists of injecting a cancer patient with a particular ligand (a molecule that binds to receptors on the surface of cells) that scientists identify by the acronym TRAIL -- for Tumor Necrosis Factor-Related Apoptosis Inducing Ligand.

Although other related proteins such as TNF and FAS have complicated research histories because of their side-effects, TRAIL has been widely considered worth serious research efforts because it triggers a sweeping death response in its target, destroying cancerous and pre-cancerous cells.

After the Nature Medicine study appeared, El-Deiry and his colleagues set out to find the key to how TRAIL works, in order to establish a method for using it safely.

That key lies in the enzyme family known as caspases.

Working first with colon cells, the researchers learned that cancerous colon cells may be destroyed through two separate actions - one of which is triggered through a caspase-8-dependent pathway, and the other through a pathway that requires caspase 9.

Then, working with human liver cells, they found the healthy cells were destroyed mainly through the caspase-9-requiring path. The human liver cells could be protected from TRAIL if that path were blocked. "When we realized that the cells have different sensitivities to these enzymes, it immediately suggested that many malignant tumor cells will be killed, but healthy cells will be preserved, if we use a combination of TRAIL plus a caspase 9 inhibitor," El-Deiry said. But there remained the problem that some cancerous cells may be destroyed only through a caspase 9-requiring pathway.

The researchers suggest solving that problem through timing: "What we are proposing is a schedule of treatments that would avoid using chemotherapy or radiation at the same time we use TRAIL with a caspase 9 inhibitor. That will increase the safety and strength of both therapies," El-Deiry said. "We think it could be something to add to other research in the setting of clinical trials. Now, at least, there is a feasible direction for its study."
-end-
He was assisted in the study by Penn collaborators Nesrin Ozoren; Kunhong Kim, MD-PhD; Timothy F. Burns; David T. Dicker, and A. David Moscioni, PhD. The study was funded by the Howard Hughes institute.

University of Pennsylvania School of Medicine

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.